Though the Sackler name was tarnished over Purdue Pharma’s role in the opioid crisis, Arthur Sackler’s should not be, she ...

Purdue Pharma has filed a new bankruptcy plan as part of a $7.4 billion settlement to resolve thousands of lawsuits over the company’s alleged role in the opioid crisis, months after the Supreme ...

The justices heard oral arguments on the plan in December. STAMFORD, CT – APRIL 2: Purdue Pharma headquarters stands in downtown Stamford, April 2, 2019 in Stamford, Connecticut. (Photo by Drew ...

In late September 2006, the recommendations for indictments were forwarded to Justice Department headquarters in Washington. A few weeks later, defense lawyers representing Purdue Pharma and the ...

Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...

Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step toward finalizing a proposed opioid settlement of at least $7.4 billion after a setback in the U.S. Supreme Court last year.

The billionaire family that owns Purdue Pharma, maker of the pain medication blamed for helping fuel the nation’s opioid crisis, has agreed to increase payments to settle long-running litigation ...

Purdue Pharma LP has filed a new Chapter 11 plan with the US Bankruptcy Court for the Southern District of New York, pledging it will give creditors including US states and other parties more than ...

Purdue Pharma, the company best known for fueling the opioid crisis by misleadingly marketing the infamous painkiller OxyContin, received approval on Wednesday for a new auto-injector device used ...

The Sacklers and Purdue Pharma boosted their settlement contribution to $7.4 billion after the U.S. Supreme Court overturned a prior settlement in June 2024. If approved, the new plan would end ...

The Supreme Court on Thursday put a bankruptcy plan for Purdue Pharma, the manufacturer of the highly addictive opioid painkiller OxyContin, on hold while it reviews a challenge to the legality of the ...